Um modelo de patogênese se baseia nos achados sobre macrófagos e funções de célula T de pacientes afetados.[28]Desnues B, Ihrig M, Raoult D, et al. Whipple's disease: a macrophage disease. Clin Vaccine Immunol. 2006 Feb;13(2):170-8.
http://cvi.asm.org/cgi/content/full/13/2/170
http://www.ncbi.nlm.nih.gov/pubmed/16467322?tool=bestpractice.com
Os macrófagos de pacientes com doença de Whipple apresentam uma capacidade persistentemente diminuída de degradar organismos intracelulares, e a T whipplei pode impedir a maturação dos fagossomos.[29]Bai JC, Sen L, Diez R, et al. Impaired monocyte function in patients successfully treated for Whipple's disease. Acta Gastroenterol Latinoam. 1996;26(2):85-9.
http://www.ncbi.nlm.nih.gov/pubmed/9137662?tool=bestpractice.com
[30]Lukacs G, Dobi S, Szabo M. A case of Whipple's disease with repeated operations for ileus and complete cure. Acta Hepatogastroenterol (Stuttg). 1978 Jun;25(3):238-42.
http://www.ncbi.nlm.nih.gov/pubmed/78655?tool=bestpractice.com
[31]Ghigo E, Capo C, Aurouze M, et al. Survival of Tropheryma whipplei, the agent of Whipple's disease, requires phagosome acidification. Infect Immun. 2002 Mar;70(3):1501-6.
http://iai.asm.org/cgi/content/full/70/3/1501
http://www.ncbi.nlm.nih.gov/pubmed/11854238?tool=bestpractice.com
A baixa produção de interleucina (IL)-12 em monócitos, baixa concentração sérica de IL-12p40 e expressão reduzida de CD11b indicam ainda um funcionamento deficiente dos macrófagos.[32]Marth T, Roux M, von Herbay A, et al. Persistent reduction of complement receptor 3 alpha-chain expressing mononuclear blood cells and transient inhibitory serum factors in Whipple's disease. Clin Immunol Immunopathol. 1994 Aug;72(2):217-26.
http://www.ncbi.nlm.nih.gov/pubmed/7519533?tool=bestpractice.com
[33]Ectors N, Geboes K, De Vos R, et al. Whipple's disease: a histological, immunocytochemical and electronmicroscopic study of the immune response in the small intestinal mucosa. Histopathology. 1992 Jul;21(1):1-12.
http://www.ncbi.nlm.nih.gov/pubmed/1378814?tool=bestpractice.com
[34]Kalt A, Schneider T, Ring S, et al. Decreased levels of interleukin-12p40 in the serum of patients with Whipple's disease. Int J Colorectal Dis. 2006 Mar;21(2):114-20.
http://www.ncbi.nlm.nih.gov/pubmed/15875203?tool=bestpractice.com
[35]Marth T, Neurath M, Cuccherini BA, et al. Defects of monocyte interleukin 12 production and humoral immunity in Whipple's disease. Gastroenterology. 1997 Aug;113(2):442-8.
http://www.ncbi.nlm.nih.gov/pubmed/9247462?tool=bestpractice.com
Os macrófagos intestinais revelam um fenótipo alternativamente ativado.[36]Desnues B, Lepidi H, Raoult D, et al. Whipple disease: intestinal infiltrating cells exhibit a transcriptional pattern of M2/alternatively activated macrophages. J Infect Dis. 2005 Nov 1;192(9):1642-6.
http://jid.oxfordjournals.org/content/192/9/1642.full
http://www.ncbi.nlm.nih.gov/pubmed/16206080?tool=bestpractice.com
[37]Moos V, Schmidt C, Geelhaar A, et al. Impaired immune functions of monocytes and macrophages in Whipple's disease. Gastroenterology. 2010 Jan;138(1):210-20.
http://www.ncbi.nlm.nih.gov/pubmed/19664628?tool=bestpractice.com
Consequentemente, bactérias invasoras são internalizadas, mas não são destruídas pelos macrófagos intestinais.
Além disso, a atividade de células T auxiliares tipo 1 (Th1) é baixa na periferia e na lâmina própria dos pacientes com doença de Whipple.[38]Marth T, Kleen N, Stallmach A, et al. Dysregulated peripheral and mucosal Th1/Th2 response in Whipple's disease. Gastroenterology. 2002 Nov;123(5):1468-77.
http://www.ncbi.nlm.nih.gov/pubmed/12404221?tool=bestpractice.com
As células Th1 específicas para T whipplei estão reduzidas ou ausentes na periferia e na mucosa.[24]Moos V, Kunkel D, Marth T, et al. Reduced peripheral and mucosal Tropheryma whipplei-specific Th1 response in patients with Whipple's disease. J Immunol. 2006 Aug 1;177(3):2015-22.
http://www.jimmunol.org/cgi/content/full/177/3/2015
http://www.ncbi.nlm.nih.gov/pubmed/16849516?tool=bestpractice.com
Por outro lado, as respostas de células Th2 funcionais aumentam nos linfócitos da periferia e da mucosa, o que está de acordo com a observação de que a T whipplei se replica em macrófagos desativados por IL-4 e IL-10.[38]Marth T, Kleen N, Stallmach A, et al. Dysregulated peripheral and mucosal Th1/Th2 response in Whipple's disease. Gastroenterology. 2002 Nov;123(5):1468-77.
http://www.ncbi.nlm.nih.gov/pubmed/12404221?tool=bestpractice.com
[39]Schoedon G, Goldenberger D, Forrer R, et al. Deactivation of macrophages with interleukin-4 is the key to the isolation of Tropheryma whippelii. J Infect Dis. 1997 Sep;176(3):672-7.
http://www.ncbi.nlm.nih.gov/pubmed/9291314?tool=bestpractice.com
O clearance imunológico prejudicado da T whipplei resulta em acúmulo maciço de bactérias em macrófagos, principalmente da mucosa intestinal, que podem ser visualizadas por coloração com ácido periódico de Schiff. Embora o órgão afetado seja principalmente o trato gastrointestinal, pode ocorrer doença isolada do SNC, endocardite infecciosa e doença articular. Nódulos subcutâneos podem se desenvolver em casos raros, e manifestações precoces também podem ser detectadas no pulmão, fígado ou músculos.[40]Friedmann AC, Perera GK, Jayaprakasam A, et al. Whipple's disease presenting with symmetrical panniculitis. Br J Dermatol. 2004 Oct;151(4):907-11.
http://www.ncbi.nlm.nih.gov/pubmed/15491437?tool=bestpractice.com
[41]Tarroch X, Vives P, Salas A, et al. Subcutaneous nodules in Whipple's disease. J Cutan Pathol. 2001 Aug;28(7):368-70.
http://www.ncbi.nlm.nih.gov/pubmed/11437943?tool=bestpractice.com
[42]Helliwell TR, Appleton RE, Mapstone NC, et al. Dermatomyositis and Whipple's disease. Neuromuscul Disord. 2000 Jan;10(1):46-51.
http://www.ncbi.nlm.nih.gov/pubmed/10677863?tool=bestpractice.com
[43]Kwee D, Fields JP, King LE Jr. Subcutaneous Whipple's disease. J Am Acad Dermatol. 1987 Jan;16(1 Pt 2):188-90.
http://www.ncbi.nlm.nih.gov/pubmed/2434537?tool=bestpractice.com
[44]Cho C, Linscheer WG, Hirschkorn MA, et al. Sarcoidlike granulomas as an early manifestation of Whipple's disease. Gastroenterology. 1984 Oct;87(4):941-7.
http://www.ncbi.nlm.nih.gov/pubmed/6205935?tool=bestpractice.com
[45]Viteri AL, Stinson JC, Barnes MC, et al. Rod-shaped organism in the liver of a patient with Whipple's disease. Dig Dis Sci. 1979 Jul;24(7):560-4.
http://www.ncbi.nlm.nih.gov/pubmed/88317?tool=bestpractice.com
[46]Puget M, Iwaz J, Tristan A, et al. Whipple's disease with muscle impairment. Muscle Nerve. 2006 Dec;34(6):794-8.
http://www.ncbi.nlm.nih.gov/pubmed/16967496?tool=bestpractice.com
[47]Misbah SA, Stirzaker D, Ozols B, et al. Anonymous survey of blood donors by polymerase chain reaction for Tropheryma whippelii. QJM. 1999 Jan;92(1):61.
http://qjmed.oxfordjournals.org/cgi/content/full/92/1/61
http://www.ncbi.nlm.nih.gov/pubmed/10209674?tool=bestpractice.com